Facilitated By

San Antonio Medical Foundation

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Study Of Acalabrutinib In Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, And Prednisone (R-CHOP) In Subjects >65 Years With Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Research Start Date

The primary objective of the study is to evaluate the effect of adding acalabrutinib to R-CHOP for progression-free survival in previously untreated non-germinal center diffuse large B-cell lymphoma.

Collaborative Project
Clinical Care
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.